ArticleScientific reports2025
Chitosan mitigates pan drug resistance in citrobacter freundii exhibiting AmpC and ESBL from Egyptian livestock.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extended-spectrum beta-lactamase (ESBL) and ampicillin resistance gene type C (ampC) in foodborne Citrobacter freundii (C. freundii) pose a severe public health risk, especially when they combine with other critical resistance genes to produce a reservoir of resistance. Therefore, the current study aimed to estimate the prevalence, phenotypic, and genotypic profiling of antimicrobial resistance in C. freundii isolates obtained from diseased broiler chickens and native Egyptian buffaloes in Kafr El-Sheikh and Dakahlia governorates, Egypt. Also, the investigation of the antibacterial activity of chitosan (CS) 1%, 2%, and chitosan nanoparticles (CSNPs), including the estimation of minimum inhibitory concentrations (MIC) and minimum bactericidal concentrations (MBC) and their combinations with ciprofloxacin (CIP), were evaluated. C. freundii was detected in 57.58% (19/33) of broiler chickens and 52.63% (20/38) of buffalo. Surprisingly, 26.32% (5/19) and 20% (4/20) of chicken and buffalo samples, respectively were multidrug-resistant (MDR), 42.11% (8/19) and 15% (3/20) were extensively drug-resistant (XDR), and 31.58% (6/19) and 65% (13/20) were pan drug-like-resistant (PDR). High frequencies of resistance genes were observed, including int1, dfrA1, sul2, aadA1, qnrA, and bla
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.